Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Shinshu University

Status and phase: Unknown; Phase 4

Conditions: Osteoporosis

Treatments: Drug: Denosumab and teriparatide treatment in osteoporotic patients; Drug: Teriparatide treatment in osteoporotic patients; Drug: Denosumab treatment in osteoporotic patients

Study type: Interventional

Funder types: Other

Identifiers

NCT02156960

Deno-PTH2365

Details and patient eligibility

About

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 1 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Osteoporotic patients

Exclusion criteria

• none

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Crossover Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Denosumab and/or teriparatide treatment

Experimental group

Description:

Denosumab and/or teriparatide treatment in osteoporotic patients

Treatment:

Drug: Teriparatide treatment in osteoporotic patients

Drug: Denosumab and teriparatide treatment in osteoporotic patients

Drug: Denosumab treatment in osteoporotic patients